Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Lymphoma 1Leukemia 1Gallbladder Neoplasms 1Cholangiocarcinoma 1Burkitt Lymphoma 1Biliary Tract Neoplasms 1

Interventions

Gemcitabine 33Cisplatin 28pembrolizumab 19durvalumab 17Oxaliplatin 16Fluorouracil 16Leucovorin 14Magnetic Resonance Spectroscopy 13Specimen Handling 9Biopsy 9lenvatinib 7Nivolumab 7Capecitabine 7Taxes 6Paclitaxel 6Irinotecan 6fludarabine 5Folfox protocol 5Drug Therapy 5Carboplatin 5Albumin-Bound Paclitaxel 5pemigatinib 4Ipilimumab 4Fluorodeoxyglucose F18 4Floxuridine 4Cyclophosphamide 4Bevacizumab 4130-nm albumin-bound paclitaxel 4tremelimumab 3olaparib 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Cholangiocarcinoma × devimistat × 1 year × Clear all
NCT04203160 2025-12-31

Gemcitabine and Cisplatin With or Without CPI-613 as First Line Therapy for Patients With Advanced Unresectable Biliary Tract Cancer (BilT-04)

University of Michigan Rogel Cancer Center

Phase 1/2 Terminated
75 enrolled 17 charts
Gastrointestinal

Biliary Tract Neoplasms, Gallbladder Neoplasms, Cholangiocarcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡